Active substance
Penciclovir
- SFDA 1
- US FDA 5
- US price lines 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Penovar | 1 % (W/W) | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DENAVIR | 1% | cream · topical | MYLAN | Prescription | 24 Sep 1996 |
| PENCICLOVIR | 1% | cream · topical | TEVA PHARMS USA | Prescription | 9 Nov 2022 |
| PENCICLOVIR | 1% | cream · topical | TORRENT | Prescription | 7 Aug 2023 |
| PENCICLOVIR | 1% | cream · topical | PADAGIS ISRAEL | Prescription | 27 Sep 2024 |
| PENCICLOVIR | 1% | cream · topical | AMNEAL | Prescription | 22 Aug 2025 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DENAVIR 1% CREAM | $155.076 | per GM | 23 Sep 2026 |
| US NADAC | PENCICLOVIR 1% CREAM | $52.1538 | per GM | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2018 DENAVIR — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.